Alkem laboratories reports strong Q2 FY26 revenue and profit growth

Alkem Laboratories Ltd. reported a 17.2% year-over-year increase in total revenue from operations to ₹40,010 million for Q2 FY26, with consolidated net profit after tax reaching ₹7,651 million, an 11.1% YoY growth. This performance was reviewed and approved by the board of directors on November 13, 2025. Standalone financial results also showed strength, with revenue from operations at ₹25,420.3 million and profit for the period at ₹7,867.3 million for Q2 FY26.

Domestic sales grew by 12.4% to ₹27,660 million, while international sales surged by 29.5% to ₹11,890 million. The company reported an EBITDA of ₹9,208 million, up 22.3% YoY, achieving an EBITDA margin of 23.0%. R&D expenses for Q2 FY26 were ₹1,302 million, representing 3.3% of total revenue. As of September 30, 2025, Alkem had filed 187 ANDAs, 2 NDAs, and 1 BLA with the USFDA, having received approvals for 163 ANDAs and 2 NDAs.

The trading window for Alkem Laboratories will open on November 17, 2025, following the communication of these financial results to the stock exchanges. An audio recording of the Q2 and H1 FY26 earnings conference call is available on the company's website for investors.